A potential activity of valproic acid in the stimulation of interleukin-3-mediated megakaryopoiesis and erythropoiesis

Experimental Hematology

Volumn 38, Issue 8, 2010, Pages 685-695

  Liu, Bing ^a   Ohishi, Kohshi ^b   Yamamura, Kentaro ^a   Suzuki, Kei ^a   Monma, Fumihiko ^a   Ino, Kazuko ^a   Masuya, Masahiro ^a   Sekine, Takao ^c   Heike, Yuji ^d   Takaue, Yoichi ^d   Katayama, Naoyuki ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

^c Matsusaka Chuo General Hospital   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD61 ANTIGEN; CYTOKINE; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; MESSENGER RNA; ROMIDEPSIN; STEM CELL FACTOR; THROMBOPOIETIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; VALPROIC ACID;

ADULT; ARTICLE; CD34 SELECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE; MALE; MEGAKARYOCYTE ERYTHROID PROGENITOR; MEGAKARYOPOIESIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD34; ERYTHROID PRECURSOR CELLS; ERYTHROPOIESIS; ERYTHROPOIETIN; GABA AGENTS; GATA1 TRANSCRIPTION FACTOR; GATA2 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; HUMANS; INTEGRIN BETA3; INTERLEUKIN-3; MEGAKARYOCYTES; MYELODYSPLASTIC SYNDROMES; RNA, MESSENGER; STEM CELLS; THROMBOPOIESIS; THROMBOPOIETIN; VALPROIC ACID;

EID: 77954536433     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.03.019     Document Type: Article

References (50)

1. Bernstein B.E., Meissner A., Lander E.S. The mammalian epigenome. Cell 2007, 128:669-681.
2. Delcuve G.P., Rastegar M., Davie J.R. Epigenetic control. J Cell Physiol 2009, 219:243-250.
3. Batty N., Malouf G.G., Issa J.P. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009, 280:192-200.
4. Dokmanovic M., Marks P.A. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005, 96:293-304.
5. Gallinari P., Di Marco S., Jones P., Pallaoro M., Steinkuhler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 2007, 17:195-211.
6. Garcia-Manero G., Issa J.P. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest 2005, 23:635-642.
7. Hadnagy A., Beaulieu R., Balicki D. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. Mol Cancer Ther 2008, 7:740-748.
8. Altucci L., Minucci S. Epigenetic therapies in haematological malignancies: searching for true targets. Eur J Cancer 2009, 45:1137-1145.
9. Gottlicher M., Minucci S., Zhu P., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978.
10. Plass C., Oakes C., Blum W., Marcucci G. Epigenetics in acute myeloid leukemia. Semin Oncol 2008, 35:378-387.
11. Ropero S., Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007, 1:19-25.
12. Bug G., Gul H., Schwarz K., et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005, 65:2537-2541.
13. De Felice L., Tatarelli C., Mascolo M.G., et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res 2005, 65:1505-1513.
14. Mahlknecht U., Schonbein C. Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells. Haematologica 2008, 93:443-446.
15. Seet L.F., Teng E., Lai Y.S., et al. Valproic acid enhances the engraftability of human umbilical cord blood hematopoietic stem cells expanded under serum-free conditions. Eur J Haematol 2009, 82:124-132.
16. Young J.C., Wu S., Hansteen G., et al. Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal. Cytotherapy 2004, 6:328-336.
17. Yamamura K., Ohishi K., Katayama N., et al. Pleiotropic role of histone deacetylases in the regulation of human adult erythropoiesis. Br J Haematol 2006, 135:242-253.
18. Goldfarb A.N. Transcriptional control of megakaryocyte development. Oncogene 2007, 26:6795-6802.
19. Iwasaki H., Mizuno S., Wells R.A., Cantor A.B., Watanabe S., Akashi K. GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages. Immunity 2003, 19:451-462.
20. Klimchenko O., Mori M., Distefano A., et al. A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell- derived primitive hematopoiesis. Blood 2009, 114:1506-1517.
21. Wickrema A., Crispino J.D. Erythroid and megakaryocytic transformation. Oncogene 2007, 26:6803-6815.
22. Duenas-Gonzalez A., Candelaria M., Perez-Plascencia C., Perez-Cardenas E., de la Cruz-Hernandez E., Herrera L.A. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008, 34:206-222.
23. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
24. Yamamura K., Ohishi K., Katayama N., et al. Notch ligand Delta-1 differentially modulates the effects of gp130 activation on interleukin-6 receptor alpha-positive and -negative human hematopoietic progenitors. Cancer Sci 2007, 98:1597-1603.
25. Mouthon M.A., Freund M., Titeux M., et al. Growth and differentiation of the human megakaryoblastic cell line (ELF-153): a model for early stages of megakaryocytopoiesis. Blood 1994, 84:1085-1097.
26. Bagley C.J., Woodcock J.M., Stomski F.C., Lopez A.F. The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors. Blood 1997, 89:1471-1482.
27. Guthridge M.A., Stomski F.C., Thomas D., et al. Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Stem Cells 1998, 16:301-313.
28. Nakahata T., Okumura N. Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers. Leuk Lymphoma 1994, 13:401-409.
29. Scicchitano M.S., McFarland D.C., Tierney L.A., Narayanan P.K., Schwartz L.W. In vitro expansion of human cord blood CD36+ erythroid progenitors: temporal changes in gene and protein expression. Exp Hematol 2003, 31:760-769.
30. Yang M., Li K., Ng M.H., et al. Thrombospondin-1 inhibits in vitro megakaryocytopoiesis via CD36. Thromb Res 2003, 109:47-54.
31. Berthier R., Valiron O., Schweitzer A., Marguerie G. Serum-free medium allows the optimal growth of human megakaryocyte progenitors compared with human plasma supplemented cultures: role of TGF beta. Stem Cells 1993, 11:120-129.
32. Halle P., Rouzier C., Kanold J., et al. Ex vivo expansion of CD34+/CD41+ late progenitors from enriched peripheral blood CD34+ cells. Ann Hematol 2000, 79:13-19.
33. Crispino J.D. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol 2005, 16:137-147.
34. Shimizu R., Yamamoto M. Gene expression regulation and domain function of hematopoietic GATA factors. Semin Cell Dev Biol 2005, 16:129-136.
35. Koschmieder S., Halmos B., Levantini E., Tenen D.G. Dysregulation of the C/EBP Differentiation Pathway in Human Cancer. J Clin Oncol 2009, 27:619-628.
36. Acharya S., Bussel J.B. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000, 22:62-65.
37. Fujieda A., Katayama N., Ohishi K., et al. A putative role for histone deacetylase in the differentiation of human erythroid cells. Int J Oncol 2005, 27:743-748.
38. Nand S., Sosman J., Godwin J.E., Fisher R.I. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood 1994, 83:357-360.
39. Nimer S.D., Paquette R.L., Ireland P., Resta D., Young D., Golde D.W. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol 1994, 22:875-880.
40. Rose C., Wattel E., Bastion Y., et al. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. Leukemia 1994, 8:1458-1462.
41. Mangi M.H., Newland A.C. Interleukin-3 in hematology and oncology: current state of knowledge and future directions. Cytokines Cell Mol Ther 1999, 5:87-95.
42. Marsh J.C., Ganser A., Stadler M. Hematopoietic growth factors in the treatment of acquired bone marrow failure states. Semin Hematol 2007, 44:138-147.
43. Jadersten M., Malcovati L., Dybedal I., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26:3607-3613.
44. Mundle S., Lefebvre P., Vekeman F., Duh M.S., Rastogi R., Moyo V. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009, 115:706-715.
45. Ganser A., Ottmann O.G., Hoelzer D. Interleukin-3 in the treatment of myelodysplastic syndromes. Int J Clin Lab Res 1992, 22:125-128.
46. Hopfer O., Komor M., Koehler I.S., et al. Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. Leuk Res 2009, 33:434-442.
47. Kuendgen A., Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007, 110:943-954.
48. Verhoef G.E., De Schouwer P., Ceuppens J.L., Van Damme J., Goossens W., Boogaerts M.A. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992, 6:1268-1272.
49. Kanda J., Chonabayashi K., Watanabe M., Arima N., Tsudo M. Successful treatment with cyclosporine of sodium valproate-induced pure red cell aplasia. Rinsho Ketsueki 2005, 46:1114-1117.
50. Bottom K.S., Adams D.M., Mann K.P., Ware R.E. Trilineage hematopoietic toxicity associated with valproic acid therapy. J Pediatr Hematol Oncol 1997, 19:73-76.